Novartis acquires biopharmaceutical group Avidity for $12bn
Global pharmaceutical and healthcare company Novartis has agreed to acquire biopharmaceutical company Avidity Biosciences for around $12 billion . The transaction is expected to close in the first half of 2026 and follows Avidity’s separation of its early-stage precision cardiology programs into a new publicly traded entity SpinCo. The move significantly strengthens Novartis’ neuroscience franchise by adding three late-stage neuromuscular…